Paper Details

  1. Home
  2. Paper Details

[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies].

Author: KrämerG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Gabapentin, a new antiepileptic drug, is effective in treating refractory partial seizures in patients over 12 years old. It has favorable pharmacokinetic data with no major drug interactions. Three placebo-controlled trials showed efficacy in reducing seizures. Tolerance is good with no serious side effects reported.
Paper Details　
Original Abstract of the Article :
Gabapentin is a new antiepileptic drug for add-on therapy in patients above the age of 12 years with otherwise refractory partial seizures. Its unknown molecular mode of action is probably related to amino-acid-related binding sites in the brain. There are no hints to toxicologic effects or damage o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8578059

データ提供：米国国立医学図書館（NLM）

Gabapentin: A New Hope for Partial Epilepsy

Epilepsy, a neurological disorder characterized by seizures, can significantly impact a person's life. This study focuses on the potential of gabapentin, a new antiepileptic drug, as an add-on therapy for patients with refractory partial seizures. The researchers investigated the drug's effectiveness, safety, and pharmacokinetic properties, aiming to shed light on its potential role in epilepsy management.

A Promising Solution: Gabapentin's Effectiveness

The study found that gabapentin showed promising results in clinical trials, demonstrating its efficacy in reducing the frequency and severity of partial seizures. Gabapentin's potential for improving seizure control offers hope for patients who have not responded well to conventional treatments.

Managing Side Effects: A Holistic Approach

While gabapentin appears to be safe and well-tolerated, the study highlights the importance of careful monitoring for potential side effects. It emphasizes the need for a personalized approach to managing epilepsy, taking into account each patient's individual needs and circumstances. This may involve careful dose adjustments and close monitoring of any adverse reactions.

Dr. Camel's Conclusion

Gabapentin represents a ray of hope for patients with partial epilepsy who have not achieved satisfactory seizure control with existing therapies. Its effectiveness, safety profile, and favorable pharmacokinetic properties make it a valuable addition to the arsenal of antiepileptic medications. This study encourages continued research to further understand and optimize the use of gabapentin in managing this complex neurological disorder.

Date :
  1. Date Completed 1996-03-14
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

8578059

DOI: Digital Object Identifier

8578059

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.